30th Anniversary Annual Scientific Meeting of the American Society of Retina Specialists

August 25–29, 2012 | Aria Resort, Las Vegas

Program updated July 19, 2012

Locations and room numbers appear in red.

The American Society of Retina Specialists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Retina Specialists designates this live activity for a maximum of 31.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Friday, August 24

5:00-8:00 PM  Meeting Registration

Saturday, August 25

10:00 AM-8:00 PM  Meeting Registration

1:00-4:10 PM  Sub-specialty Reviews (Bristlecone 9, 10)

  1:00-2:00 PM  Uveitis Update, Narsing Rao, MD
  2:05-3:05 PM  Glaucoma Update, Rohit Varma, MD
  3:10-4:10 PM  Neuro-Ophthalmology Update, Anthony Arnold, MD

4:30-6:30 PM  Retina Case Conference (Bristlecone 5, 6)

  4:33:00-4:37:30 PM  Acute Retinal Necrosis following Varicella Zoster Vaccination, Jay Stewart, MD
  4:37:30-4:42:00 PM  Cystoid Macular Edema Secondary to \textit{M. tuberculosis} Infection, Guillermo Salcedo-Villanueva, MD
  4:42:00-4:46:30 PM  Duchenne Muscular Dystrophy-Associated Proliferative Retinal Vasculopathy Successfully Treated with Laser Photocoagulation, Paul Hahn, MD
  4:46:30-4:51:00 PM  Bilateral Macular and Peripheral Chorioretinopathy of Unknown Origin, Grant Comer, MD
  4:51:00-4:55:30 PM  Hyperautofluorescent Ring in Autoimmune Retinopathy, Luiz Lima, MD
  4:55:30-5:00:00 PM  Anterior Uveitis and Peripapillary Hemorrhage...Find the Culprit!, Humberto Ruiz-Garcia, MD
5:00:00-5:04:30 PM  Indolent Choroidal Mass with Retinal Detachment, Rajiv Anand, MD
5:04:30-5:09:00 PM  An Unusual Cause of Choroidal Neovascularization, Greg Kokame, MD
5:09:00-5:13:30 PM  I See Spots, Richard Spaide, MD
5:13:30-5:18:00 PM  Older Individual with Placoid Retinal Lesions, Paracentral Scotomas, and Preceding Viral Meningitis, Stephen Davis, MD
5:18:00-5:22:30 PM  Peripheral Retinal Vasculitis Demonstrated by Ultra-Widefield Fluorescein Angiography in Preeclampsia with HELLP Syndrome, Phoebe Lin, MD
5:22:30-5:27:00 PM  Occlusive Vasculitis Related to Human Adjuvant (HAD), Gabriela Lopezcarasa Hernandez, MD
5:27:00-5:31:30 PM  Mystery Case, David Sarraf, MD
5:31:30-5:36:00 PM  Unknown Case, J. Fernando Arevalo, MD
5:36:00-5:40:30 PM  Fulminant Retinochoroiditis and Papillitis presenting as Acute Posterior Multifocal Placoid Pigment Epitheliopathy, Christine Kay, MD
5:40:30-5:45:00 PM  Endogenous Candida Endophthalmitis (ECE) Presenting as Chronic Uveitis, Tidarat Prechanond, MD
5:45:00-5:49:30 PM  Consecutive Macular Fold Formation and Subfoveal Perfluorocarbon Liquid Bubble in a Staphylomatous Eye following Retinal Detachment Repair: Management, Michael Colucciello, MD
5:49:30-5:54:00 PM  Endogenous Candida albicans Endophthalmitis following Spontaneous Abortion and IUD Removal, Theodore Leng, MD
5:54:00-5:58:30 PM  Acute Syphilitic Posterior Placoid Chorioretinitis (ASPPC) in an Immunocompetent Patient with Neurosyphilis Presenting as CME after Cataract Surgery, Jeffrey Gross, MD
5:58:30-6:03:00 PM  Interesting Spectral-Domain Optical Coherence Tomography Finding in a 12-Year-Old Girl with Posterior Uveitis, Robin Ray, MD
6:03:00-6:07:30 PM  Macular Detachment Associated with Chronic Retained Intraocular Foreign Body (IOFB), Omar Punjabi, MD
6:07:30-6:12:00 PM  Macular Schisis Associated With Diffuse Choroidal Hemangioma in Sturge-Weber Syndrome, Rithwick Rajagopal, MD
6:12:00-6:16:30 PM  New Onset Bilateral Chorioretinal Folds with Symptomatic Worsening Over 2 Years, Amy Babiuch, MD
6:16:30-6:21:00 PM  Retinal Vasculitis Associated with Dermatomyositis, a Rare Ophthalmic Manifestation, Matthew Ohr, MD
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:21:00-6:25:30 PM</td>
<td>Two Sisters with Unilateral Exudative Retinal Detachment, Lynn Huang, MD</td>
</tr>
<tr>
<td>6:25:30-6:30:00 PM</td>
<td>Bilateral Severe Retinopathy with Macular Edema, Armando Sandoval, MD</td>
</tr>
<tr>
<td>6:30-9:30 PM</td>
<td>Welcome Reception (Level 3)</td>
</tr>
</tbody>
</table>

**Sunday, August 26**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM-5:30 PM</td>
<td>Meeting Registration</td>
</tr>
<tr>
<td>7:00-8:00 AM</td>
<td>Breakfast (Pinyon Hall)</td>
</tr>
<tr>
<td>7:00 AM-5:30 PM</td>
<td>Exhibit Hall Open (Pinyon Hall)</td>
</tr>
<tr>
<td>7:30-7:35 AM</td>
<td>Welcome—John Thompson, MD (Bristlecone 5, 6)</td>
</tr>
<tr>
<td>7:35-9:37 AM</td>
<td>AMD I Symposium (Bristlecone 5, 6)</td>
</tr>
<tr>
<td>7:35-7:43 AM</td>
<td>Age-related Differences in the Prevalence of Genetic Risk Markers in Patients with Intermediate AMD, Carl Awh, MD</td>
</tr>
<tr>
<td>7:43-7:51 AM</td>
<td>Systemic Complement Inhibition with Eculizumab for the Treatment of Geographic Atrophy in AMD: The COMPLETE Study, Zohar Yehoshua, MD</td>
</tr>
<tr>
<td>7:51-7:59 AM</td>
<td>Systemic Complement Inhibition with Eculizumab for the Treatment of Drusen in AMD: The COMPLETE study, Philip Rosenfeld, MD</td>
</tr>
<tr>
<td>7:59-8:05 AM</td>
<td>Discussion</td>
</tr>
<tr>
<td>8:05-8:13 AM</td>
<td>Baseline Predictors of Visual Outcomes and Treatment Frequency in Patients with Wet Age-Related Macular Degeneration (AMD) in the First Year of HARBOR, Brandon Busbee, MD</td>
</tr>
<tr>
<td>8:13-8:21 AM</td>
<td>Early OCT Responses at Day 7 and Month 1 Post Ranibizumab that Predict Visual Acuity Outcomes and Injection Frequency at Month 12 in the HARBOR Study, Srinivas Sadda, MD</td>
</tr>
<tr>
<td>8:21-8:29 AM</td>
<td>Association of Best-corrected Visual Acuity (BCVA) Gains at Month 12 in the HARBOR Study with Change in Choroidal Neovascularization (CNV) Area, Karl Csaky, MD</td>
</tr>
<tr>
<td>8:29-8:35 AM</td>
<td>Discussion</td>
</tr>
<tr>
<td>8:35-8:43 AM</td>
<td>Retinal Pigment Epithelial Cell Loss in Patients with Neovascular Age-Related Macular Degeneration, Richard Spaide, MD</td>
</tr>
</tbody>
</table>
8:43-8:51 AM  2 mg Ranibizumab for Fibrovascular Pigment Epithelial Detachments in AMD Refractory to Standard Dosing: The HiPED Study, Anne Fung, MD

8:51-8:55 AM  Discussion

8:55-9:03 AM  Correlation of Retinal Morphology and Visual Acuity in the Comparisons of Age-Related Macular Degeneration Treatments Trial (CATT), Glenn Jaffe, MD

9:03-9:11 AM  Genetic Variants in CFH and CFHR5 Show an Association with Phenotypic Subtypes of Exudative ARMD and with a Response to Anti-VEGF Monotherapy, Mark Nelson, MD

9:11-9:19 AM  Flexible Macular Capillary Recruitment in Relative Hypoxia as a Homeostatic Adaptation with Pathologic Implications, Joseph Maguire, MD

9:19-9:25 AM  Discussion

Rapid-Fire Papers

9:25-9:29 AM  Human Adenovirus Infection Induces RPE Death: Implications for the Pathogenesis of Atrophy, Lucian Del Priore, MD

9:29-9:33 AM  Sub-Retinal Catheterization Ab-Externo as a Method to Deliver Cell Therapy for the Treatment of Advanced Geographic Atrophy, Tom Chang, MD

9:33-9:37 AM  Discussion

9:37-10:07 AM  Break

10:07-11:32 AM  Awards Ceremony (Bristlecone 5, 6)

10:07-10:12 AM  Pyron Award Intro - John Thompson, MD

10:12-10:42 AM  Pyron Award – 2-Year Results from the Comparison of AMD Treatment Trials (CATT) - Daniel Martin, MD

10:42-10:47 AM  Founders Award Intro - Suber Huang, MD

10:47-11:17 AM  Founders Award - Retina 2017: Passengers in the Nitroglycerine Truck - David Parke, II, MD

11:17-11:22 AM  Young Physicians Section - Crystal Apple Award

11:22-11:27 AM  Foundation of ASRS Report - Mark Hammer, MD

11:27-11:32 AM  Retina Image Bank - Suber Huang, MD

11:32-11:37 PM  PAT Survey Presentation – J. Michael Jumper, MD (Bristlecone 5, 6)

11:37 AM-12:05 PM  ASRS Business Meeting (member’s only) (Bristlecone 5, 6)

11:37-11:42 AM  RAFA Update - Larry Halperin, MD
1:15-2:39 PM  
**Macular Surgery I Symposium (Bristlecone 5, 6)**

1:15-1:23 PM  
“Foveal Red Spot,” “Macular Microhole” and “Foveal Photoreceptor Defect” in the Era of High-Resolution Optical Coherence Tomography, Edward Hall, MD

1:23-1:31 PM  
Surgical Outcomes of Macular Holes Associated with Idiopathic Macular Telangiectasia, Judy Kim, MD

1:31-1:39 PM  
Supra Choroidal Buckling: a Novel Approach in Treating Vitreomacular Interface Disorders in Severe Myopia: Initial 1-year Data, Ehab El-Rayes, MD

1:39-1:45 PM  
Discussion

**Rapid-Fire Papers**

1:45-1:49 PM  
Vitrectomy Outcomes for Lamellar Macular Holes Associated with Epiretinal Membranes, John Thompson, MD

1:49-1:53 PM  
Longitudinal Analysis of the 2008-2010 Medicare Claims Database for Newly Diagnosed Macular Holes, Peter Kaiser

1:53-1:57 PM  
Outcomes and Predictive Factors in Bilateral Macular Holes, Emmanuel Chang, MD

1:57-2:01 PM  
25-gauge Vitrectomy for Macular Holes with and without Retinal Detachment in Highly Myopic Eyes, Francesco Boscia, MD

2:01-2:09 PM  
Discussion

2:09-2:13 PM  
Outcomes of Macular Hole Surgery with Broad ILM Peeling and No Face-Down Positioning, Raymond Iezzi, MD

2:13-2:17 PM  
OCT-Guided Face-Down Positioning for Macular Hole Surgery, Sumit Shah, MD

2:17-2:21 PM  
Triamcinolone Acetonide (TA) Assisted Removal of Internal Limiting Membrane (ILM), Homayoun Tabandeh, MD

2:21-2:27 PM  
Discussion

2:27-2:31 PM  
Ocriplasmin for the Treatment of Patients with VMT and Full-Thickness Macular Hole: Subgroup Responder Analyses from the Phase III MIVI-TRUST Program, Carl Regillo, MD

2:31-2:35 PM  
Ocriplasmin Single Intravitreal Injection for the Resolution of Symptomatic Vitreomacular Adhesion including Macular Hole: MIVI-TRUST Safety Findings, Baruch Kuppermann, MD

2:35-2:39 PM  
Discussion
2:45-3:10 PM Vitreoretinal Surgery Challenges – Moderator Kirk Packo, MD, Panelists: William Aylward, MD, Allen Ho, MD, George Williams, MD, Stanislao Rizzo, MD (Bristlecone 5, 6)

3:10-3:40 PM Break

3:40-4:36 PM Imaging Symposium (Bristlecone 5, 6)

3:40-3:48 PM Acute Macular Neuroretinopathy (AMN): New Insights into Diagnosis, Natural History and Pathogenesis as Revealed by Sequential Multimodal Imaging, David Sarraf, MD

3:48-3:56 PM Pre-clinical Evaluation and Intraoperative Human Retinal Imaging with a Microscope-Integrated Spectral Domain Optical Coherence Tomography Device, Paul Hahn, MD

3:56-4:00 PM Discussion

Rapid-Fire Papers

4:00-4:04 PM PIONEER: A Prospective Intraoperative and Perioperative OCT Study—6-Month Vitreoretinal Results, Justis Ehlers, MD

4:04-4:08 PM Automated Drusen Segmentation and Quantification in SD-OCT Images, Theodore Leng, MD

4:08-4:12 PM Does Spectral Domain OCT Provide Any Additional Information to Non-Mydriatic Fundus Photography Screening?, Rishi Singh, MD

4:12-4:16 PM Functional Retinal Imaging with Triple-wavelength Imaging Reflectometry (TIR), Kristie Lin, MD

4:16-4:24 PM Discussion

4:24-4:28 PM Microglia in Retina - Can We See Them In vivo?, Gennady Landa, MD

4:28-4:32 PM Effect of Area of Peripheral Retinal Non-Perfusion on Treatment Response in Branch and Central Retinal Vein Occlusion, Michael Singer, MD

4:32-4:36 PM Discussion

4:36-5:42 PM Retinal Vascular Symposium (Bristlecone 5, 6)

4:36-4:44 PM Increased Vision with QLT091001 in Blindness due to Mutations in RPE65 or LRAT Genes, David Saperstein, MD

4:44-4:52 PM Macular Telangiectasia Type 2: Is It a Vascular or Degenerative Disease?, Emily Chew, MD
Intravitreal Aflibercept Injection in Central Retinal Vein Occlusion: Results of the Phase 3 COPERNICUS Study, David Boyer, MD

5:06-5:10 PM Time to Clinically Significant Visual Acuity Gains following Ranibizumab Treatment for Retinal Vein Occlusion: BRAVO and CRUISE Trials, Allen Thach, MD

5:10-5:14 PM Anti-VEGF Therapy Significantly Reduces the Rate of Neovascular Glaucoma Due to Central Retinal Vein Occlusion, Hua Gao, MD

5:14-5:18 PM A Cohort Study of Surgical Transvenous Chorioretinotomies for Macular Edema Due to Retinal Vein Occlusion, Jeffrey Luttrull, MD

5:18-5:24 PM Discussion

5:24-5:28 PM Restoration of Blood Flow and Vision in Non-Arteritic Central Retinal Artery Occlusion by Early Vitrectomy, Shlomit Schaal, MD

5:28-5:32 PM The CT "Crescent Sign" is Highly Predictive of Vision Loss in Patients with Terson Syndrome, Michael Stewart, MD

5:32-5:36 PM Valproic Acid Treatment of Chronic Central Serous Chorioretinopathy, Richard Rosen, MD

5:36-5:42 PM Discussion

Free Evening

Monday, August 27

6:30 AM-6:30 PM Meeting Registration

7:00-8:00 AM Breakfast (Pinyon Hall)

7:00 AM-6:30 PM Exhibit Hall Open (Pinyon Hall)

7:30-9:36 AM Diabetic Retinopathy I Symposium (Bristlecone 5, 6)

Rapid-Fire Papers

7:30-7:34 AM A Novel Collaborative Multi-Center Telemedicine Diabetic Retinopathy Assessment Program, Ingrid Zimmer-Galler, MD

7:34-7:38 AM Identification of Diabetic Retinopathy Genes through a Genome-Wide Association Study among Mexican-Americans, Victor Gonzalez, MD
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:38-7:42 AM</td>
<td>Navigated Macular Laser Therapy Results in Stabilizing Diabetic Macular Edema (DME)</td>
<td>William Freeman, MD</td>
</tr>
<tr>
<td>7:42-7:48 AM</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>7:48-7:52 AM</td>
<td>Intravitreal Bevacizumab for Recurrent Vitreous Hemorrhage after Vitrectomy for Diabetic Retinopathy</td>
<td>Mathew MacCumber, MD</td>
</tr>
<tr>
<td>7:52-7:56 AM</td>
<td>Rapid Progression of Proliferative Retinopathy despite Extensive Panretinal Photocoagulation: Could Early Vitrectomy have Saved the Eye?</td>
<td>Anina Abraham, MD</td>
</tr>
<tr>
<td>7:56-8:00 AM</td>
<td>Transvitreal Fibrinoid Pseudo-Endophthalmitis after Diabetic Vitrectomy</td>
<td>Caesar Luo, MD</td>
</tr>
<tr>
<td>8:00-8:06 AM</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>8:06-8:14 AM</td>
<td>36-Month Efficacy and Safety Results of RISE and RIDE, 2 Phase III Randomized Controlled Clinical Trials of Ranibizumab for Diabetic Macular Edema</td>
<td>David Brown, MD</td>
</tr>
<tr>
<td>8:14-8:22 AM</td>
<td>A Prospective Randomized Trial of Intravitreal Bevacizumab versus Ranibizumab for the Management of Diabetic Macular Edema</td>
<td>Rodrigo Jorge, MD</td>
</tr>
<tr>
<td>8:22-8:30 AM</td>
<td>0.5 mg and 2 mg Ranibizumab in Patients Unresponsive or with Incomplete Response to Bevacizumab for the Treatment of Diabetic Macular Edema</td>
<td>Dante Pieramici, MD</td>
</tr>
<tr>
<td>8:30-8:36 AM</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>8:36-8:44 AM</td>
<td>Estimate of Vision of Impairment or Legal Blindness Avoided in the U.S. with Ranibizumab for Central-Involved Diabetic Macular Edema with Vision Loss</td>
<td>Neil Bressler, MD</td>
</tr>
<tr>
<td>8:44-8:52 AM</td>
<td>Combined Intravitreal Injection of a Rho-Kinase Inhibitor (Fasudil) and Bevacizumab for Persistent Diabetic Macular Edema</td>
<td>Hamid Ahmadieh, MD</td>
</tr>
<tr>
<td>8:52-8:56 AM</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>8:56-9:04 AM</td>
<td>Integrin Peptide Therapy: The Human Experience in DME</td>
<td>Hugo Quiroz-Mercado, MD</td>
</tr>
<tr>
<td>9:04-9:12 AM</td>
<td>Visual Acuity and OCT Outcomes following Cataract Extraction in Eyes with Diabetic Macular Edema</td>
<td>Michael Scott, MD</td>
</tr>
<tr>
<td>9:12-9:20 AM</td>
<td>Risk of Endophthalmitis after Intravitreal Drug Injections with and without Use of Topical Antibiotics in DRCR Randomized Clinical Trials</td>
<td>Abdhish Bhavsar, MD</td>
</tr>
<tr>
<td>9:20-9:26 AM</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Topic</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>9:26-9:46 AM</td>
<td>Ocular Oncology (Bristlecone 5, 6)</td>
<td>Intravitreal High Dose (2 mg) Ranibizumab for Recalcitrant Radiation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Outcomes after Plaque with Vitrectomy and Silicone Oil for Choroidal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maculopathy, Paul Finger, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td>9:46-10:16 AM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:16-11:51 AM</td>
<td>Socioeconomic Sessions (Bristlecone 5, 6)</td>
<td>Accountable Care Organizations - What You Don’t Know May Hurt You</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Risks and Opportunities from Health Care Reform</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FDA Approval Process for Ophthalmic Drugs Used to Treat Retinal Diseases, Wiley Chambers, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Real-World Utilization of Intravitreal Anti-Vascular Endothelial Growth Factor Agents in Retinal Diseases: A Claims Analysis from 2006 to 2011, Nancy Holekamp, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Practice Analytics in Retina Practice Management, Trexler Topping, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td>11:51-1:05 PM</td>
<td>General Lunch (Pinyon Hall); Women in Retina (WinR) Lunch (Bristlecone 9, 10)</td>
<td></td>
</tr>
<tr>
<td>1:05-2:49 PM</td>
<td>AMD II Symposium (Bristlecone 5, 6)</td>
<td>96 Weeks Results from the VIEW 1 and VIEW 2 Studies: Intravitreal Aflibercept Injection versus Ranibizumab for Neovascular AMD, Allen Ho, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Incidence of Non-Infectious Intraocular Inflammation after Intravitreal Aflibercept Injection, Daniel Roth, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td></td>
<td>Rapid-Fire Papers - Initial Experiences with Aflibercept</td>
<td></td>
</tr>
<tr>
<td>1:25-1:29 PM</td>
<td></td>
<td>VEGF Trap-Eye (Aflibercept) Effectiveness in Wet AMD Patients Recalcitrant to Ranibizumab and Bevacizumab, Rizwan Bhatti, MD</td>
</tr>
<tr>
<td>1:29-1:33 PM</td>
<td></td>
<td>The Initial Response to Aflibercept for Neovascular AMD with Persistent Fluid on OCT (Non-Responders), Patrick Williams, MD</td>
</tr>
</tbody>
</table>
1:33-1:37 PM Resolution of Persistent Macular Edema, SRF and/or RPE Detachment After Single Injection of Aflibercept in Patients with Neovascular AMD, Ashish Sharma, MD

1:37-1:41 PM Pigment Epithelial Detachment Improvement in Non-Naive Neovascular AMD Patients after Intravitreal Aflibercept, James Major, MD

1:41-1:49 PM Discussion

1:49-1:53 PM Aflibercept for Patients Previously Treated with Anti-VEGF Therapy for Age-Related Macular Degeneration, Irene Barbazetto, MD

1:53-1:57 PM Initial Experience with Aflibercept in the Management of Patients with Persistent Exudation Due to AMD Undergoing Chronic Ranibizumab Therapy, Kirk Packo, MD

1:57-2:01 PM Intravitreal Aflibercept in Eyes with Active Choroidal Neovascularization (CNV) Secondary to AMD after Multiple Ranibizumab or Bevacizumab Injections, Jonathan Prenner, MD

2:01-2:05 PM Aflibercept for Exudative AMD Suboptimally Responsive to Ranibizumab and Bevacizumab, Chirag Shah, MD

2:05-2:09 PM Initial Early Clinical Experience with Aflibercept for Wet Age-Related Macular Degeneration, Philip Ferrone, MD

2:09-2:19 PM Discussion

2:19-2:27 PM Presentation Title TBA, Pravin Dugel, MD

2:27-2:35 PM Visual and Anatomic Outcomes of Anti-VEGF therapy in Exudative AMD and Vitreomacular Interface Disease, Sophie Bakri, MD

2:35-2:43 PM Quantitative Determination and Comparison of Intravitreal Cytokines in DRP, RVO and ARMD, Michael Koss, MD

2:43-2:49 PM Discussion

2:49-3:14 PM Macular Degeneration with Choroidal Neovascularization - Which Drug and How Often? - Moderator: Neil Bressler, MD, Panelists: David Boyer, MD, Dennis Han, MD, Daniel Martin, MD, Glenn Jaffee, MD (Bristlecone 5, 6)

3:14-3:44 PM Break

3:44-5:24 PM Retinal Surgery I Symposium (Bristlecone 5, 6)

3:44-3:52 PM Vitreoretinal Traction and Effectiveness of a Modified Vitrectomy Probe in Small-Gauge Vitrectomy: Experimental and Clinical Study, Stanislao Rizzo, MD

3:52-4:00 PM Two-Year Results from the Argus(R) II Retinal Prosthesis System Clinical Trial, Mark Humayun, MD
Discussion

Combined Vitrectomy with Gas Tamponade and Posterior Glaucoma Tube Placement in the Management of Complicated Uveitic Glaucoma, E. Opremcak, MD

Rate of Sclerotomy Suturing in 23-Gauge and 25-Gauge Vitrectomy Surgery, Kourous Rezaei, MD

Discussion

Rapid-Fire Papers

Evaluation of Wound Closure Morphology of Sclerotomy Sites Using Anterior Segment Spectral Domain Optical Coherence tomography (AS OCT), Manish Nagpal, MD

Wound Closure Evaluated with Optical Coherence Tomography after 25-Gauge Vitrectomy, Makoto Inoue, MD

Translational Development of a Subretinal Delivery System for Cell-Based Products, Michael Samuel, MD

Discussion

Risk of Iatrogenic Retinal Tears in Small-Gauge Vitrectomy (PPV) is Reduced by Initiating Surgery with Peripheral PPV Rather than Traditional Core PPV, Renaud Duval, MD

Novel Changes to Retinal Anatomy as Imaged by Intraoperative Optical Coherence Tomography during Repair of Rhegmatogenous Retinal Detachment, Matthew Ohr, MD

A Mechanics-Based Model of a Detaching Retina, Howard Fine, MD

Unplanned Return to the Operating Room following Vitreoretinal Surgery, Jay Stewart, MD

Discussion

Ophthalmicedge.org Version 2.0: Expansion and Analytics of a Free Educational Website, Yale Fisher, MD

Determining Construct Validity of the Posterior Segment Anti-Tremor, Bimanual, and Forceps Training Modules on the EYESi Virtual Reality Simulator, Colin McCannel, MD

Combined Scleral Tunnel Fixated Posterior Chamber Intraocular Lens and Pars Plana Vitrectomy in the Management of Posteriorly Dislocated Lenses, Edmund Wong, MD
Tuesday, August 28

7:00 AM-6:00 PM  Meeting Registration

7:00-8:00 AM  Breakfast (Pinyon Hall)

7:00 AM-2:00 PM  Exhibit Hall Open (Pinyon Hall)

7:30-7:48 AM  Trauma/Pharmacology Symposium (Bristlecone 5, 6)

Rapid-Fire Papers

7:30-7:34 AM  Airsoft BBs: The Blinding Truth, Timothy Saunders, MD

7:34-7:38 AM  Autofluorescence, OCT, EDI-OCT, and Management of Acute Subfoveal Hemorrhage Secondary to Blunt Trauma +/-Parafoveal Choroidal Rupture, Pradeepa Yoganathan, MD

7:38-7:42 AM  Bacterial Susceptibility Profiles in Trauma-Associated Endophthalmitis, Duncan Friedman, MD

7:42-7:48 AM  Discussion

7:48-8:38 AM  Inflammation Symposium (Bristlecone 5, 6)

7:48-7:56 AM  Characteristics, Complications, and Surgical Outcomes of Panuveitis over 25 Years: The KKESH Uveitis Survey Study Group, J. Fernando Arevalo, MD

7:56-8:04 AM  Voclosporin: Efficacy and Safety in Non-Infectious Uveitis Involving the Posterior Segment, Shree Kurup, MD

8:04-8:12 AM  Clinical Utility of Serologic and Radiologic Testing in the Evaluation of the White Dot Syndromes, Steven Yeh, MD

8:12-8:18 AM  Discussion

8:18-8:26 AM  Fluocinolone Acetonide Implant versus Systemic Therapy For Non-Infectious Uveitis: Combined Results Of Three Clinical Trials, Sunil Srivastava, MD

8:26-8:34 AM  Visual Outcomes in Uveitis with Angiographic Macular Leakage Treated with the Fluocinolone Acetonide (Retisert) Implant or Standard Treatment, Thomas Albini, MD
8:34-8:38 AM  Discussion

8:38-9:30 AM  Infections Symposium (Bristlecone 5, 6)

8:38-8:46 AM  Antibacterial Properties of 2 Percent Lidocaine on *Staphylococcus* and *Streptococcus* Species and Reduced Rate of Post-injection Endophthalmitis, Stephen Kim, MD

8:46-8:54 AM  Laboratory Investigation of an Endophthalmitis Outbreak Caused by *Streptococcus Mitis/Oralis* Group after Intravitreal Injection of Bevacizumab, Harry Flynn, MD

8:54-9:02 AM  Outbreak of Fusarium Endophthalmitis following Brilliant Blue G (BBG) Dye-Assisted Vitrectomy Procedures, Michael Davis, MD

9:02-9:10 AM  Endophthalmitis Following Vitrectomy: A Prospective & Nationwide UK Study, Somdutt Prasad, MD

9:10-9:18 AM  Discussion

Rapid-Fire Papers

9:18-9:22 AM  Microbiologic Analysis in Office-Based Micro-Incision Vitrectomy Surgery, Flavio Rezende, MD

9:22-9:26 AM  Pars Plana Vitrectomy in the Management of Patients Diagnosed with Endophthalmitis following Intravitreal Anti-VEGF Injection, Juan Romero, MD

9:26-9:30 AM  Discussion

9:26-9:56 AM  Break

9:56-10:56 AM  AMD III Symposium (Bristlecone 5, 6)

9:56-10:04 AM  Response to Treat & Extend Therapy in wAMD Patients Shows Differentially Expressed Proteins Specific to CNV Signaling Pathways Shed into the Vitreous, Bert Glaser, MD

10:04-10:12 AM  Visual Acuity Response as a Function of the Affinity and Vitreous Half-Life of Intravitreally-Administered Anti-VEGF Agents, Robert Avery, MD

10:12-10:20 AM  Intraocular Pressure in Patients with Neovascular AMD Receiving Intravitreal Aflibercept Injection or Ranibizumab, K. Freund, MD

10:20-10:26 AM  Discussion

10:26-10:34 AM  Autologous Transplantation of RPE and Choroid for the Treatment of Wet AMD: Functional Results and Prognostic Factors after a Long-Term Follow-up, Barbara Parolini, MD
10:34-10:42 AM  Patient Perceptions of the Treatment Regimen and Expected Outcomes of Intravitreal Anti-VEGF Injections for Wet Age-Related Macular Degeneration, Tarek Hassan, MD

10:42-10:50 AM  PEARL2: High-Dose 2 mg Ranibizumab, Continuous Monthly Treatment, for Polypoidal Choroidal Vasculopathy (PCV) – 6-Month Results, Gregg Kokame, MD

10:50-10:56 AM  Discussion

10:56 AM-12:22 PM  Retinal Surgery II Symposium (Bristlecone 5, 6)

10:56-11:04 AM  MIVS 23-Gauge Pars Plana Vitrectomy Management of Complex Retinal Detachment in Eyes with Brachytherapy Treated Posterior Uveal Melanoma, Timothy Murray, MD

11:04-11:12AM  Pars Plana Vitrectomy with Medium-Term Perfluoro-n-octane for Recurrent Inferior Retinal Detachment Complicated by Proliferative Vitreoretinopathy, Steve Charles, MD

11:12-11:20 AM  23-Gauge Endoscopic Vitrectomy for Complicated Retinal Diseases, Jeffrey Heier, MD

11:20-11:26 AM  Discussion

11:26-11:34 AM  Oral Fluoroquinolones and the Risk of Retinal Detachment, David Maberley, MD

11:34-11:42 AM  Pneumatic Retinopexy in 1000 eyes with Rhegmatogenous Retinal Detachment: What have we learned?, Thierry Verstraeten, MD

11:42-11:46 AM  Discussion

Rapid-Fire Papers

11:46-11:50 AM  Optic Neuropathy following Vitrectomy for Retinal Detachment: Clinical Features and Analysis of Risk Factors, Alok Bansal, MD

11:50-11:54 AM  The Minimally Invasive 25-Gauge Vitreoretinal Surgery with Perfluoropropane or Air Tamponade in the Treatment of Rhegmatogenous Retinal Detachments, Cesare Mariotti, MD

11:54-11:58 AM  Epiretinal Membrane Formation and Cystoid Macular Edema following Uncomplicated Primary Retinal Detachment Repair with Small-Gauge Pars Plana Vitrectomy, Gayatri Reilly, MD

11:58-12:04 PM  Discussion

12:04-12:08 PM  Retained Subretinal Perfluorocarbon Liquid in Sutureless 23-Gauge versus Sutured 20-Gauge Vitrectomy for Retinal Detachment Repair, Sunir Garg, MD
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:08-12:12 PM</td>
<td>Comparative Study of Vitrectomy with and without Internal Limiting Membrane peeling for Rhegmatogenous Retinal Detachment, Cyrus Shroff, MD</td>
</tr>
<tr>
<td>12:12-12:16 PM</td>
<td>Inferno Temporal Dialysis: a genetic RRD in the Andes?, Armando Sandoval, MD</td>
</tr>
<tr>
<td>12:16-12:22 PM</td>
<td>Discussion</td>
</tr>
<tr>
<td>12:25-1:25 PM</td>
<td>General Lunch (Pinyon Hall); SIG Luncheons (Pinyon 1,2,3) – Organizer: Sophie Bakri, MD</td>
</tr>
<tr>
<td>1:30-5:30 PM</td>
<td>Concurrent Instructional Courses</td>
</tr>
<tr>
<td>1:30-2:30 PM</td>
<td>Vitreous Manipulation with Ocriplasmin (Bluethorn 6,7,8)</td>
</tr>
<tr>
<td></td>
<td>Director: M. Trese, MD</td>
</tr>
<tr>
<td>1:30-2:30 PM</td>
<td>Use of Surgeon-Curved Vitrectomy Cutter for Improved Performance during Retinal Detachment Repair (Bristlecone 4)</td>
</tr>
<tr>
<td></td>
<td>Director: A. Korotkin, MD</td>
</tr>
<tr>
<td>1:30-2:30 PM</td>
<td>Real World Retina 101: How to Establish the Type of Career You Want (Bristlecone 7)</td>
</tr>
<tr>
<td></td>
<td>Director: N. Choudhry, MD; Faculty: V. Hau, MD, PhD</td>
</tr>
<tr>
<td>1:30-2:30 PM</td>
<td>Pneumatic Retinopexy: Pearls and Pitfalls (Bristlecone 9)</td>
</tr>
<tr>
<td></td>
<td>Director: E. Mavrikakis, MD; Faculty: W. Lam, MD, FRCS(C); V. Chaudhary, MD; S. Conti, MD; R. Muni, MD, MD, MSC, FRSC</td>
</tr>
<tr>
<td>1:30-2:30 PM</td>
<td>Newer Advances in Vitreo-Retina Surgeries: Tools and Techniques (Bluethorn 3,4,5)</td>
</tr>
<tr>
<td></td>
<td>Director: S. Natarajan, MD; Faculty: M. Nagpal, MD, FRCS (UK); Y. Oshima, MD, PhD; M. Goyal, MD; P. Dugel, MD; E. El-Rayes, MD, Ph.D; C. Awh, MD; A. Banker, MD; G. Shah, MD</td>
</tr>
<tr>
<td>1:30-2:30 PM</td>
<td>ICG/Multimodality Imaging for the Diagnosis and Management of Exudative Age-Related Macular Degeneration (Bristlecone 3)</td>
</tr>
<tr>
<td></td>
<td>Director: M. Nelson, MD</td>
</tr>
<tr>
<td>1:30-3:25 PM</td>
<td>ASRS Research and Development Committee Symposium: Clinical Trials &quot;Unplugged&quot;: Real, Practical Questions and Answers (Bristlecone 10)</td>
</tr>
<tr>
<td></td>
<td>Director: P. Dugel, MD; Faculty: A. Ho, MD; D. Martin, MD; D. Brown, MD; D. Boyer, MD; J. Heier, MD; M. Singer, MD; P. Kaiser, MD; T. Murray, MD, MBA; W. Mieler, MD; J. Jumper, MD; B. Kuppermann, MD, PhD; R. Avery, MD</td>
</tr>
<tr>
<td>1:30-3:30 PM</td>
<td>Anterior Segment Surgery for the Vitreoretinal Surgeon: Discussion and Wetlab (Bristlecone 1,2)</td>
</tr>
<tr>
<td></td>
<td>Director: C. Awh, MD; Faculty: C. Baker, MD; F. Rezende, MD, PhD; S. Rizzo, MD; F. Boscia, MD; J. Prenner, MD; G. Rocha, MD</td>
</tr>
</tbody>
</table>
1:30-2:30 PM  
Electronic Health Records - What You Need to Know for Successful Selection and Implementation (Bristlecone 8)  
Director: C. McCannel, MD

2:45-3:45 PM  
‘First 20 Dates with Internal Limiting Membrane’ – Tips on Macular Surgery Techniques for Beginners (Bluethorn 3,4,5)  
Director: M. Soni, MD; Faculty: L. Gopal, MS, FRCs; S. Charles, MD; G. Aylward, MD, FRCs, FRCOPth

2:45-4:45 PM  
RETINAWS: When the Going Gets Tough, the Tough Get Going: Challenging Cases in Vitreoretinal Surgery (Bristlecone 4)  
Director: K. Rezaei, MD; Faculty: K. Packo, MD,FACS; A. Banker, MD; H. Tabandeh, MD; E. El-Rayes, MD,Ph.D; M. MacCumber, MD, PhD; G. Williams, MD; J. Arumi, MD, PhD

2:45-3:45 PM  
Intravitreal Injection Technique: Focusing on Patient Comfort and Safety (Bristlecone 9)  
Director: N. Gregori, MD; Faculty: H. Flynn, MD

2:45-3:45 PM  
High-Stakes Vitrectomy: Vitreoretinal Surgery in Inflamed Eyes (Bluethorn 6,7,8)  
Director: T. Albini, MD; Faculty: S. Yeh, MD; S. Bakri, MD; C. Flaxel, MD

2:45-3:45 PM  
Pathologic Myopia: Diagnosis and Management of Tractional and Non-Tractional Complications (Bristlecone 7)  
Director: B. Parolini, MD

2:45-3:45 PM  
EHR 101: How to Select the Right EHR for You and Get Paid for It (Bristlecone 8)  
Director: S. Logani, MD

2:45-3:45 PM  
Advanced OCT Interpretations: The Vitreomacular Interface (Bristlecone 3)  
Director: W. Lam, MD; Faculty: E. Mavrikakis, MD, PhD; S. Yong, BSc(Hons), MD, MMEd, FRCSE, FAMS; V. Chaudhary, MD

3:35-5:30 PM  
Challenge the Masters (Bristlecone 10)  
Director: C. Mein, MD; Faculty: V. Morales-Canton, MD; G. Lopezcarasa Hernandez, MD

4:00-5:00 PM  
Uveitis Blackjack: Hitting 21 Every Time (Bristlecone 7)  
Director: S. Yeh, MD; Faculty: T. Albini, MD; S. Srivastava, MD; H. Fine, MD, MHSc

4:00-5:00 PM  
Pearls of Electronic Health Record (EHR) And Image Data Management Implementation (Bristlecone 8)  
Director: R. Singh, MD; Faculty: Joel Pearlman, MD, PhD; Robert C. Wang, MD

4:00-5:00 PM  
Intravitreal Injections: Sound Technique and Risk Reduction (Bristlecone 9)  
Director: A. Bhavsar, MD; Faculty: R. Jager, MD, MBA; D. Williams, MD, MBA
4:00-5:00 PM Bi-manual Small-Gauge Vitreous Surgery for Complicated Retinal Detachment Repair (Bristlecone 3)  
Director: C. Chen, MD

4:00-5:00 PM Combined Phaco-Vitrectomy: Tips and Tricks (Bluethorn 6,7,8)  
Director: E. Wong, MD; Faculty: D. Wong, MD; Y. Yeo, MBBS,FRCS; B. Loh, MBBS, FRCEd

4:00-5:00 PM Adobe Bridge, Adobe Lightroom 4, and Adobe Photoshop CS6 Extended for Ophthalmic Imaging: An Overview (Bluethorn 3,4,5)  
Director: W. Mieler, MD

6:30 PM Reception (Pinyon 1,2,3 and Pre-function area)

7:30 PM-midnight Gala Dinner (Bristlecone 5,6) and Umbo Lounge (HAZE nightclub)

Wednesday, August 29

7:30-8:30 AM Breakfast

8:00 AM-noon Meeting Registration

8:30-9:30 AM Macular Surgery II/Anterior Segment Surgery Symposium (Bristlecone 5, 6)

8:30-8:34 AM Postoperative Posterior Segment Complications in Eyes Treated with the Boston Type I Keratoprosthesis, Darin Goldman, MD

8:34-8:38 AM Trans-Scleral Fixation of Foldable Akreos Posterior Chamber in Intraocular Lens Implants with 25-Gauge Vitrectomy: A Large Single Surgeon Case Series, Daniel Adelberg, MD

8:38-8:42 AM Visual and Surgical Outcome of Surgery (Retrieval, Suturing or Secondary Implant) for Posteriorly Dislocated IOLs in a Single Retina Procedure, Rajiv Anand, MD

8:42-8:48 AM Discussion

8:48-8:52 AM Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study: Baseline Findings, Maziar Lalezary, MD

8:52-8:56 AM Correlation between the Unaided Observation of the ILM & Brilliant Blue-Stained ILM following ERM Peeling: Results of the PACORES Group, Lihteh Wu, MD

8:56-9:00 AM Intraoperative Optical Coherence Tomography Use during Epimacular Membrane Removal with Internal Limiting Membrane Peeling, Ching Chen, MD

9:00-9:06 AM Discussion
9:06-9:10 AM  Structural and Functional Implications of Severe Foveal Dystopia in Epiretinal Membranes, Amani Fawzi

9:10-9:14 AM  Functional Outcome in Patients with Posterior Vitrectomy after Idopathic Epiretinal Membrane from 2007 to 2011, Boris Bajaire, MD

9:14-9:18 AM  Epiretinal Membrane Progression Occurs in Exudative Age-Related Macular Degeneration and May Contribute to Poorer Anatomical and Functional Outcomes, Omar Punjabi, MD

9:18-9:22 AM  Natural Clinical Course of Unoperated Eyes with Vitreomacular Traction Syndrome, Vishak John, MD

9:22-9:30 AM  Discussion

9:30-10:00 AM  AMD IV Symposium (Bristlecone 5, 6)

9:30-9:34 AM  Vascularized Pigment Epithelial Detachment Treated with 0.5 mg versus 2 mg Ranibizumab: Analysis of Results Based on Lesion Subtypes, Clement Chan, MD

9:34-9:38 AM  Juxtapapillary Retinal Pigment Epithelial Detachments in Asymptomatic Subjects Detected with Spectral Domain Optical Coherence Tomography, Alexander Walsh, MD

9:38-9:42 AM  Discussion

9:42-9:46 AM  A Phase 1 Study Targeting Tissue Factor with a Single Dose of Intravitreal hIL-1 for Exudative Age-Related Macular Degeneration (AMD), Christine Gonzales, MD

9:46-9:50 AM  Argon Laser with and without Anti-Vascular Endothelial Growth Factor Therapy (VEGF) for Polypoidal Choroidal Vasculopathy, Yew San Ian Yeo, MD

9:50-9:54 AM  Combination Therapy for Neovascular AMD Using PRN Ranibizumab and a Single Injection of Liquid Sustained Release Intravitreal Triamcinolone Acetonide, Jennifer Lim, MD

9:54-10:00 AM  Discussion

10:00-10:48AM  Pediatric Retina Symposium (Bristlecone 5, 6)

10:00-10:08 AM  Fluorescein Angiographic Findings in Spontaneously Regressing Stage 1 or 2 Retinopathy of Prematurity, Virgilio Morales-Canton, MD

10:08-10:16 AM  Safety and Efficacy of 137 Intravitreal Bevacizumab Injections without Laser as Primary Therapy for ROP with 5 Years of Follow-up, Alay Banker, MD

10:16-10:24 AM  Systemic and Ocular Adverse Events after 334 Injections of Intravitreal Bevacizumab in the Treatment of ROP: 5-Year Follow-up, Maria Martinez-Castellanos, MD
Discussion

Late Complications of Non-Enzymatic Vitrectomy in Infants, Michael Trese, MD

Candida Lens Abscess in Premature Infants, G. Hubbard, MD

Digital Fluorescein Angiography Guided Treatment for Pediatric Retinal Diseases, Audina Berrocal, MD

Discussion

Diabetic Retinopathy II Symposium (Bristlecone 5, 6)

Exploratory Analysis of Diabetic Retinopathy Progression through 3 Years in a Randomized Clinical Trial Evaluating Ranibizumab and Triamcinolone, Carl Baker, MD

VEGF Plasma Level of Patients with Diabetic Macular Edema after Intravitreal Injection of Bevacizumab, Ranibizumab and Pegaptanib, Gerhard Kieselbach, MD

Discussion

Outcomes of Pars Plana Vitrectomy for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy, Elliott Sohn, MD

Rapid-Fire Papers

Diabetic Retinopathy Lesions and Photoreceptor Mosaic Changes as Assessed with Ultrahigh Resolution Adaptive Optics Scanning Laser Ophthalmoscopy, Jennifer Sun, MD

Discussion

Instrumentation/Pharmacology Symposium (Bristlecone 5, 6)

A Small-Gauge Fragmatome and Method for Removal of Retained Lens Fragments, William Foster, MD

Pilot Evaluation of a New Portable Small-Gauge Vitrectomy Unit, Thomas Aaberg Jr., MD

Benefit of Direct-View for Submacular Surgery, Zhizhong Ma, MD

Electronic Reading Devices Increase Reading Speed and Comfort in Patients with Moderate Vision Loss, Daniel Roth, MD

Discussion

Initial Experience with Oral Rifampin for Treatment of Central Serous Chorioretinopathy, Zac Ravage, MD
11:52-11:56 AM  Early Detection of Functional Changes Using Microperimetry on Patients with Subclinical Hydroxychloroquine Toxicity, Clement Chow, MD

11:56-noon  Discussion

Noon  Conclusion—John Thompson, MD